Plecanatide is a guanylate cyclase-C agonist. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Plecanatide has an FDA-approved product on the U.S. market, marketed as Trulance Immediate Release under application NDA208745.
The current label is held by Salix Pharmaceuticals Inc.
From the FDA label
is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). TRULANCE is a guanylate cyclase-C agonist indicated in adults for treatment of: chronic idiopathic constipation (CIC).Quoted from the FDA-approved prescribing information
Boxed warning
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS TRULANCE is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration [see Contraindications, Use in Specific Populations ]. Avoid use of TRULANCE in patients 6 years to less than 18 years of age [see Warnings and Precautions, Use in Specific Populations ]. The safety and effectiveness of TRULANCE have not been established in patients less than 18 years of age [see Use in Specific Populations ]. WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS See full prescribing information for complete boxed Quoted from the FDA-approved prescribing information
The evidence
One source on Plecanatide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Plecanatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides